This trial aims to investigate the role of the patient's own stem cells in cardiomyopathy. The trial is being conducted by the National University of Malaysia in conjunction with Cytopeutics Pte Ltd and proposes to recruit 80 patients with end stage cardiomyopathy that has not responded to conventional therapy. Participants will be randomly divided between two groups. A control group will receive only conventional therapy, while an experimental group will receive mesenchymal stem cells obtained from their own bone marrow directly into their heart. Participants will be monitored for complications and changes in clinical condition. This Phase II study follows on from a Phase I study by the same investigators.